CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice. Arthritis Rheum. 60 , 123–132 (2009). Article CAS Google Scholar ...

然而，自CTLA-4、PD-1和PD-L1抑制剂，靶向CD19、BCMA的免疫疗法获得成功以来 ... 该系列试验，并没有使用TIGIT作为生物标志物，但Treg细胞中较高的TIGIT:CD226比率，与接受ICIs治疗的晚期黑色素瘤患者不良临床结果相关，这代表了一个可能值得进一步探索的生物标志 ...

Foxp3 may steer T cells down specific pathways by amplifying and stabilizing features advantageous to Treg differentiation, such as CD25 and CTLA-4 expression, or by repressing features ...

研究最多的癌症中T细胞的扰动是外周抑制性CD4+调节性T（Treg）细胞的扩增及其 ... 在治疗之前并不存在。此外，抗CTLA-4也被证明能显著增加黑色素 ...

C ytotoxic T-lymphocyte antigen 4 (CTLA-4) is a protein receptor on T immune cells that prevents the cells from killing other ...

Specifically, LD IL-2 is a cytokine essential for the enhancement of Treg function and numbers suppressing ... which is the combination of COYA 301 and CTLA-4 Ig (commercially known as Abatacept ...

What does this CTLA-4 do? It is responsible for controlling regulatory T-cells, which, if found in the tumor microenvironment, are bad because they stop immune cells from being able to effectively ...

Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatmentIn a patient with a heavily pretreated leiomyosarcoma, BT ...

Turbocharge the Development of Best-In-Class Treg-Directed Therapies, Maximising Stability and Function to Deliver Safe, Scalable and Efficacious Therapies Globally As Biopharma turn their focus ...

Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that updated data from the clinical trial of botensilimab and ...

Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy ... Pe’er D, Rudensky AY. Cell. 2019 Oct 31;179(4):846-863.e24. PMID: ...

Tumor Microenvironment CD8 T and Treg Cells-related Genes Signature Distinguishes Distinct Prognosis and Targeted Therapies Response in Endometrial Cancer.